Journal of Clinical Endocrinology & Metabolism, Vol 71, 1339-1343, Copyright © 1990 by Endocrine Society

ARTICLES

Plasma transport of the 20,000-dalton variant of human growth hormone (20K): evidence for a 20K-specific binding site

G Baumann and MA Shaw
Department of Medicine, Northwestern University Medical School, Chicago, Illinois 60611.

The 20,000-dalton variant of human GH (20K) is known to circulate in blood, but few details are known about its plasma transport. A substantial portion of 20K appears to be protein bound despite its low affinity for the receptor-related GH-binding protein (BP). We, therefore, investigated the binding pattern of 20K in human plasma. Radioiodinated 20K was incubated with plasma or plasma fractions, and the mixture was fractionated by gel filtration. Saturation/Scatchard analysis was performed with both 20K and 22,000-dalton GH (22K). The majority (approximately 80%) of protein-bound 20K was complexed with a low affinity BP (Ka = approximately 2 x 10(5) M-1), with the remainder complexed with the high affinity2 receptor-related BP. The binding of 20K to the low affinity BP was specific for 20K; it may involve a 20K- specific binding site on the previously described low affinity plasma BP (peak I) or a separate 20K-specific BP. 22K did not interact with this binding site/BP. Analysis of the 20K-BP complex by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and isoelectric focusing suggested, but did not prove, the existence of a separate BP for 20K. We conclude that 20K in plasma binds primarily to a low affinity, 20K- specific binding site (possibly a new, third GH-BP), with only a small fraction bound to the GH receptor-related BP. This binding pattern is markedly different from that of 22K, which is predominantly bound to the receptor-related BP. The existence of a 20K-specific binding site/BP suggests an as yet unrecognized role for this GH variant.

This article has been cited by other articles:

				Y. Hashimoto, T. Kamioka, M. Hosaka, K. Mabuchi, A. Mizuchi, Y. Shimazaki, M. Tsunoo, and T. Tanaka Exogenous 20K Growth Hormone (GH) Suppresses Endogenous 22K GH Secretion in Normal Men J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 601 - 606. [Abstract] [Full Text]

				B. Tsunekawa, M. Wada, M. Ikeda, H. Uchida, N. Naito, and M. Honjo The 20-Kilodalton (kDa) Human Growth Hormone (hGH) Differs from the 22-kDa hGH in the Effect on the Human Prolactin Receptor Endocrinology, September 1, 1999; 140(9): 3909 - 3918. [Abstract] [Full Text]

				M. Ishikawa, S. Yokoya, K. Tachibana, Y. Hasegawa, T. Yasuda, E. Tokuhiro, Y. Hashimoto, and T. Tanaka Serum Levels of 20-Kilodalton Human Growth Hormone (GH) Are Parallel Those of 22-Kilodalton Human GH in Normal and Short Children J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 98 - 104. [Abstract] [Full Text]

				A. Edens and F. Talamantes Alternative Processing of Growth Hormone Receptor Transcripts Endocr. Rev., October 1, 1998; 19(5): 559 - 582. [Abstract] [Full Text]

				C. L. Boguszewski, P.-A. Svensson, T. Jansson, R. Clark, L. M. S. Carlsson, and B. Carlsson Cloning of Two Novel Growth Hormone Transcripts Expressed in Human Placenta J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2878 - 2885. [Abstract] [Full Text]

				C. L. Boguszewski, C. Jansson, M. C. S. Boguszewski, S. Rosberg, B. Carlsson, K. Albertsson-Wikland, and L. M. S. Carlsson Increased Proportion of Circulating Non-22-Kilodalton Growth Hormone Isoforms in Short Children: A Possible Mechanism for Growth Failure J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 2944 - 2949. [Abstract] [Full Text] [PDF]

				C. L. Boguszewski, G. Johannsson, B.-A. Bengtsson, A. Johansson, B. Carlsson, and L. M. S. Carlsson Circulating Non-22-Kilodalton Growth Hormone Isoforms in Acromegalic Men before and after Transsphenoidal Surgery J. Clin. Endocrinol. Metab., May 1, 1997; 82(5): 1516 - 1521. [Abstract] [Full Text] [PDF]